Welcome to our dedicated page for Sage Therapeutics news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutics stock.
Sage Therapeutics, Inc. (SAGE) is a pioneering, neuroscience-focused biopharmaceutical company dedicated to developing medicines for life-threatening and rare central nervous system (CNS) disorders. Founded in 2010, Sage Therapeutics aims to improve the lives of patients suffering from various CNS diseases through breakthrough scientific research, robust clinical trials, and strong partnerships.
The company is primarily engaged in three key focus areas: depression, neurology, and neuropsychiatry. Sage's lead compound, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE), marking the first of many potential seizure medicines in its extensive pipeline. Another notable treatment, Zurzuvae, targets postpartum depression (PPD) in adults, while Zulresso is a CIV injection designed for individuals aged 15 and older dealing with PPD.
In addition to these approved treatments, the company’s pipeline features several promising compounds, including SAGE-324 and Dalzanemdor (SAGE-718), which are currently under various stages of development. Sage Therapeutics leverages two critical CNS receptor systems, GABA and NMDA, to develop its innovative treatments.
Sage’s commitment to compelling science and robust clinical foundations is fortified by its world-class team of founders, advisors, investors, scientists, and managers. The company prides itself on its collaborative efforts, fostering strategic partnerships to enhance its research and development capabilities. These efforts underscore Sage Therapeutics' mission to discover, develop, and deliver significant new medicines to address unmet medical needs in the CNS space.
Sage Therapeutics and Biogen announced positive topline results from the Phase 2 KINETIC Study of SAGE-324 for essential tremor treatment. The study achieved its primary endpoint with a significant reduction in upper limb tremor score, showing a 36% decrease in the SAGE-324 group versus 21% in placebo (P=0.049). Severe tremor patients demonstrated an even greater 41% reduction. Safety profiles were consistent with previous data, and plans for further development of SAGE-324 are underway, reflecting the substantial unmet medical need in treating essential tremor affecting over 6.4 million in the U.S.
Sage Therapeutics (NASDAQ: SAGE) announced its participation in the Stifel 3rd Annual CNS Day fireside chat on March 31, 2021, at 8:00 am ET. This event highlights Sage's commitment to developing innovative therapies for brain disorders. Investors can access a live webcast on the company's investor page, with a replay available two hours post-event and archived for 30 days. Sage Therapeutics focuses on transforming treatment approaches for depression, neurology, and neuropsychiatry, aiming to improve brain health and patient outcomes.
Sage Therapeutics reported 12-month data from the Phase 3 SHORELINE Study evaluating zuranolone for major depressive disorder (MDD). The 30 mg cohort demonstrated favorable safety, with 51% reporting at least one adverse event, consistent with previous studies. 73.5% of patients achieved a clinical response, requiring an average of 2.2 treatments within the year. Interim data from the 50 mg cohort showed 80.5% response rates. Sage aims to provide further data at upcoming conferences, while continuing to assess zuranolone’s long-term efficacy and safety.
Sage Therapeutics (NASDAQ: SAGE) announced the departure of Chief Operating Officer Mike Cloonan, effective May 3, 2021. Cloonan, who has been with the company for four years, expressed intentions to pursue a Chief Executive Officer role in the biopharmaceutical sector. CEO Barry Greene commended Cloonan for his contributions and confirmed that his responsibilities will be temporarily assumed by Greene as Sage continues its growth strategy. The company remains focused on advancing its multiple brain health programs and has no immediate plans to fill the COO position.
Sage Therapeutics reported strong financial results for Q4 and the full year 2020, driven by a collaboration with Biogen valued at $3.1 billion. In Q4, Sage posted a net income of $974.9 million, significantly up from a net loss of $168.7 million in 2019. Revenue reached $1.1 billion, primarily from the Biogen partnership. Sage's cash position improved to $2.1 billion, facilitating ongoing development efforts including 10 anticipated data readouts in 2021 across its brain health portfolio. The company is focused on advancing its pipeline for major depressive disorder and other neurological conditions.
Sage Therapeutics (NASDAQ: SAGE) will present at two upcoming investor conferences in February and March 2021. The conferences are the SVB Leerink Partners' 10th Annual Global Healthcare Conference on February 25 at 8:00 am ET and the Cowen & Co. 41st Annual Health Care Conference on March 1 at 4:00 pm ET. Investors can access live webcasts of the presentations on Sage's investor website, with replays available 30 days post-event. Sage is focused on creating innovative therapies for brain disorders, aiming to enhance treatment options and improve patient outcomes.
Sage Therapeutics (NASDAQ: SAGE) will host a webcast on February 24, 2021, at 8:00 a.m. ET to announce its fourth quarter and full year 2020 financial results, alongside recent business updates. The broadcast will be accessible through the investor page of Sage's website, with a replay available post-event for 30 days. Sage Therapeutics focuses on innovative therapies for brain disorders, with an aim to revolutionize treatment approaches in depression, neurology, and neuropsychiatry.
Sage Therapeutics (NASDAQ: SAGE) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, where CEO Barry Greene will present the company's progress and plans for 2021. Key highlights include the advancement of SAGE-718, SAGE-689, and SAGE-904 into further development phases. The company recently secured $1.525 billion from a collaboration with Biogen to develop zuranolone for major depressive disorder and other conditions, bolstering its cash position to $2.1 billion. Sage anticipates several critical data readouts from its clinical programs this year.
Sage Therapeutics (NASDAQ: SAGE) has announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2021, at 10:50 a.m. ET. The event will be live-streamed on Sage's investor page, with a replay available for 30 days post-conference. Sage focuses on developing innovative therapies aimed at improving brain health for individuals facing severe brain disorders, including depression and neuropsychiatric conditions. The company aims to transform treatment approaches and enhance patient outcomes.
Sage Therapeutics (NASDAQ: SAGE) has appointed Barry Greene as its new chief executive officer, effective immediately. Greene, previously president of Alnylam Pharmaceuticals, aims to leverage his expertise to accelerate Sage's growth in developing therapies for brain disorders. Jeff Jonas, former CEO, transitions to chief innovation officer to focus on pipeline expansion and neuroscience expertise. The board expressed confidence in Greene's leadership to drive commercialization and innovation at Sage, enhancing its pathways to address patient needs in mental health treatments.
FAQ
What is the current stock price of Sage Therapeutics (SAGE)?
What is the market cap of Sage Therapeutics (SAGE)?
What is Sage Therapeutics, Inc. focused on?
What are the key focus areas of Sage Therapeutics?
What are some of the main products of Sage Therapeutics?
What is SAGE-547?
What are the current projects in Sage Therapeutics' pipeline?
What receptor systems does Sage Therapeutics target?
When was Sage Therapeutics founded?
Who makes up the team at Sage Therapeutics?
What is the mission of Sage Therapeutics?
How does Sage Therapeutics enhance its research and development capabilities?
